ADCETRIS

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug ADCETRIS contains one active pharmaceutical ingredient (API):

1 Brentuximab vedotin UNII 7XL5ISS668 - BRENTUXIMAB VEDOTIN

Brentuximab vedotin is an antibody drug conjugate (ADC) that delivers an antineoplastic agent that results in apoptotic cell death selectively in CD30-expressing tumour cells. Nonclinical data suggest that the biological activity of brentuximab vedotin results from a multi-step process. Binding of the ADC to CD30 on the cell surface initiates internalisation of the ADC-CD30 complex, which then traffics to the lysosomal compartment. Within the cell, a single defined active species, MMAE, is released via proteolytic cleavage. Binding of MMAE to tubulin disrupts the microtubule network within the cell, induces cell cycle arrest and results in apoptotic death of the CD30-expressing tumour cell. Read about Brentuximab vedotin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ADCETRIS Powder for concentrate for solution	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX05	Brentuximab vedotin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10166C, 10171H, 10172J, 10180T, 11067L, 11073T, 11079D, 11080E, 11086L, 11087M, 11089P, 11096B, 11651F, 11660Q, 11661R, 11664X
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 501115010024502
Country: CA	Health Products and Food Branch	Identifier(s): 02401347
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 18-MBE-1214
Country: EE	Ravimiamet	Identifier(s): 1597967
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 112794001, 112794001IP
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 095175
Country: FR	Base de données publique des médicaments	Identifier(s): 68438457
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 215727
Country: HK	Department of Health Drug Office	Identifier(s): 63483
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7193
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291425D1021
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1068355, 1082316
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 103993
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100285152
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W61128001
Country: SG	Health Sciences Authority	Identifier(s): 14477P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699456790058
Country: US	FDA, National Drug Code	Identifier(s): 51144-050
Country: ZA	Health Products Regulatory Authority	Identifier(s): 48/26/0433